(SWOG) studies, demonstrated significantly higher CR rates and superior event-free and overall survival with autotransplant. 6,7 Similar therapy has been administered to Data from 225 multiple myeloma (MM) patients, undergoing peripheral stem cell (PBSC) mobilization patients у60 to determine if they too benefit from such therapy. with high-dose cyclophosphamide and hematopoietic growth factors, were analyzed for median CD34
+ 70 years (median age 52 years), received autotransplants following high-dose melphalan 200 mg/m 2 as part of an cells collected or time to engraftment occurred between age groups, when adjusted for duration of prior therinstitutional review board (IRB)-approved tandem transplant protocol. Fifty-seven of the 225 patients were у60 apy. These data support the concept that autotransplants can be performed safely in patients у60 years years. During this time period, an additional 43 patients у60 years of age were evaluated for autotransplant, but did and that these patients should not be excluded from the most effective treatment modalities.
not undergo stem cell mobilization, because of poor general condition (Karnofsky score р60%), inadequate cardioKeywords: peripheral stem cell; autotransplantation; geriatrics pulmonary function (left ventricular ejection fractionϽ50; forced expiratory volume/s or DLCO Ͻ50% of predicted), abnormal renal function (creatinine у3 mg/dl) or refusal. Hence 56% of patients between the ages of 60 and 70 Cancer incidence is more than 10-fold higher in patients referred for autotransplantation did undergo stem cell mobiage 65 and older than in younger patients. Fifty-eight per lization. The characteristics of all patients receiving transcent of all cancers and 67% of all cancer mortality occurs plants are listed in Table 1 . These variables were similar in in the older segment of the population. Projections of the the different age groups, except for beta-2-microglobulin, National Cancer Institute's Surveillance, Epidemiology and with significantly more patients у60 years old having elevEnd Results (SEER) data estimate that by the year 2030, ated levels (P = 0.002), indicating a higher tumor burden 70% of cancer patients will be 65 years or older.
1,2 Justifiin this group. ably, older cancer patients are as likely to want the most Peripheral stem cell (PBSC) for two autotransplants were effective treatment for their malignancy.
3 Therefore, effeccollected prior to the first transplant using high-dose cyclotive treatment strategies in model diseases, that are tolerated phosphamide 6 g/m 2 and granulocyte-macrophage colonyby the older patient, must be developed. Ideally, such approaches should have no greater acute or long-term tox- able for the quality of PBSC collections in our previous study.
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Results
No age-related differences in the number of CD34
+ cells collected and infused were observed (Figure 1) . Similarly, age did not influence hematopoietic recovery after first or second transplant. Prolonged duration of prior standard therapy beyond 12 and especially beyond 24 months compromised the procurement of CD34 + cells and time to engraftment in all age groups (Figure 1) . Median times to recovery of granulocytes to Ͼ0.5 × 10 9 /l and platelets Ͼ50 × 10 9 /l were comparable in all age groups (Figure 2 ). However, transplant-related mortality within 60 days after transplant was 9% (n = 5) in patients у60 vs 0% among shown in Figure 3 . Although a better EFS was observed in patients Ͻ60 years (P = 0.006), the OS was not signifistimulating factor (GM-CSF, 250 g/m 2 Immunex, Seattle, cantly different in both age groups (P = 0.06, Figure 3 ). WA, USA). All 57 patients у60 have completed one autotransplant and 103 patients Ͻ60 and 29 patients у60, have completed two transplants. All patients gave informed conDiscussion sent before participating in these clinical trials. Details have been described elsewhere.
8-10 Patient data were analyzed by age group (20-49, 50-59 and у60 years) but also Autotransplants result in superior complete remission, EFS and OS in myeloma patients when compared to standardaccording to the duration of prior therapy (р12 months, 13-24 months and Ͼ24 months) representing the key varidose chemotherapy. 6, 7 The median age of patients with MM Figure 2 Median time to neutrophil (ANC Ͼ500/l) and platelet (Ͼ50 000/l) recovery, as a function of age and first or second transplant. Even with a trend to more extensive prior therapy, time to recovery in patients у60 was no different than younger patients, even at the time of second transplant.
risks of treatment-related leukemia not only for patients Ͻ60, but also for patients у60 who may reasonably be expected to have a 10-20 year median survival if diseasespecific mortality can be reduced. Decrement in toxicity and improvement in survival both argue strongly for consideration of autotransplantation in patients у60. 
